![Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial | BMC Cancer | Full Text Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-023-11287-2/MediaObjects/12885_2023_11287_Fig1_HTML.png)
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial | BMC Cancer | Full Text
![PDF) Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements PDF) Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements](https://i1.rgstatic.net/publication/360458750_Inter-Laboratory_Concordance_of_Cerebrospinal_Fluid_and_Serum_Kappa_Free_Light_Chain_Measurements/links/62921ddf6886635d5caa4d28/largepreview.png)
PDF) Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements
![Biomolecules | Free Full-Text | Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements Biomolecules | Free Full-Text | Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements](https://pub.mdpi-res.com/biomolecules/biomolecules-12-00677/article_deploy/html/images/biomolecules-12-00677-g001.png?1652167063)